Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Net Cash Flow (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Net Cash Flow readings, the most recent being -$30885.0 for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 33.9% to -$30885.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $40867.0, a 670.45% increase, with the full-year FY2024 number at -$3827.0, down 152.9% from a year prior.
  • Net Cash Flow hit -$30885.0 in Q3 2025 for Goldenwell Biotech, down from $59380.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $59380.0 in Q2 2025 to a low of -$917090.0 in Q4 2022.
  • Median Net Cash Flow over the past 5 years was -$12506.0 (2021), compared with a mean of -$56050.7.
  • Biggest five-year swings in Net Cash Flow: soared 14130.99% in 2021 and later plummeted 4633.86% in 2022.
  • Goldenwell Biotech's Net Cash Flow stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 104.5% to $41312.0 in 2023, then increased by 8.08% to $44649.0 in 2024, then crashed by 169.17% to -$30885.0 in 2025.
  • The last three reported values for Net Cash Flow were -$30885.0 (Q3 2025), $59380.0 (Q2 2025), and -$32277.0 (Q1 2025) per Business Quant data.